

# CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/CB3DBAA8B17EN.html>

Date: February 2021

Pages: 44

Price: US\$ 125.00 (Single User License)

ID: CB3DBAA8B17EN

## Abstracts

CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacture of compound biological substances. CEL-SCI's lead candidate, Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines, CEL-2000 and CEL-4000 for rheumatoid arthritis using Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.

### CEL-SCI Corp Key Recent Developments

Feb 16,2021: CEL-SCI reports first quarter fiscal 2021 financial results

Dec 30,2020: CEL-SCI reports fiscal 2020 financial results and clinical & corporate developments

Aug 11,2020: CEL-SCI reports third quarter fiscal 2020 financial results

May 11,2020: CEL-SCI reports second quarter fiscal 2020 financial results

Mar 24,2020: Covid-19: CEL-SCI to develop therapy; Soligenix works on vaccine

**Key benefits of buying this profile include:**

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

## Contents

Table of Contents

List of Tables

List of Figures

### **SECTION 1 - ABOUT THE COMPANY**

CEL-SCI Corp - Key Facts

CEL-SCI Corp - Key Employees

CEL-SCI Corp - Key Employee Biographies

CEL-SCI Corp - Major Products and Services

CEL-SCI Corp - History

CEL-SCI Corp - Company Statement

CEL-SCI Corp - Locations And Subsidiaries

Head Office

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview

CEL-SCI Corp - Business Description

CEL-SCI Corp - Corporate Strategy

CEL-SCI Corp - SWOT Analysis

SWOT Analysis - Overview

CEL-SCI Corp - Strengths

CEL-SCI Corp - Weaknesses

CEL-SCI Corp - Opportunities

CEL-SCI Corp - Threats

CEL-SCI Corp - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

CEL-SCI Corp, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Feb 16, 2021: CEL-SCI reports first quarter fiscal 2021 financial results

Dec 30, 2020: CEL-SCI reports fiscal 2020 financial results and clinical & corporate developments

Aug 11, 2020: CEL-SCI reports third quarter fiscal 2020 financial results

May 11, 2020: CEL-SCI reports second quarter fiscal 2020 financial results

Mar 24, 2020: Covid-19: CEL-SCI to develop therapy; Soligenix works on vaccine

Mar 09, 2020: CEL-SCI initiates development of immunotherapy to treat COVID-19 coronavirus infection

Feb 10, 2020: CEL-SCI reports first quarter fiscal 2020 financial results

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

CEL-SCI Corp, Key Facts  
CEL-SCI Corp, Key Employees  
CEL-SCI Corp, Key Employee Biographies  
CEL-SCI Corp, Major Products and Services  
CEL-SCI Corp, History  
CEL-SCI Corp, Key Competitors  
CEL-SCI Corp, Ratios based on current share price  
CEL-SCI Corp, Annual Ratios  
CEL-SCI Corp, Annual Ratios (Cont...1)  
CEL-SCI Corp, Interim Ratios  
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
CEL-SCI Corp, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

CEL-SCI Corp, Performance Chart (2016 - 2020)

CEL-SCI Corp, Ratio Charts

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

### COMPANIES MENTIONED

ImmunoGen Inc

Aduro BioTech Inc

Biopolymer Innovations Llc

Lentigen Technology Inc



## I would like to order

Product name: CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/CB3DBAA8B17EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CB3DBAA8B17EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970